Effects of nonspecific beta-adrenergic stimulation and blockade on blood coagulation in hypertension

J Appl Physiol (1985). 2003 Apr;94(4):1455-9. doi: 10.1152/japplphysiol.00892.2002. Epub 2002 Dec 13.

Abstract

A hypercoagulable state might contribute to increased atherothrombotic risk in hypertension. The sympathetic nervous system is hyperactive in hypertension, and it regulates hemostatic function. We investigated the effect of nonspecific beta-adrenergic stimulation (isoproterenol) and blockade (propranolol) on clotting diathesis in hypertension. Fifteen hypertensive and 21 normotensive subjects underwent isoproterenol infusion in two sequential, fixed-order doses of 20 and then 40 ng. kg(-1). min(-1) for 15 min/dose. Thirteen subjects were double-blind studied after receiving placebo or propranolol (100 mg/day) for 5 days each. In hypertensive subjects, isoproterenol elicited a dose-dependent increase in plasma von Willebrand factor (vWF) antigen [F(2,34) = 5.02; P = 0.032] and a decrease in D-dimer [F(2,34) = 4.57; P = 0.040], whereas soluble tissue factor remained unchanged. Propranolol completely abolished the increase in vWF elicited by isoproterenol [F(1,12) = 10.25; P = 0.008] but had no significant effect on tissue factor and D-dimer. In hypertension, vWF is readily released from endothelial cells by beta-adrenergic stimulation, which might contribute to increased cardiovascular risk. However, beta-adrenergic stimulation alone may not be sufficient to trigger fibrin formation in vivo.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / pharmacology*
  • Adrenergic beta-Antagonists / pharmacology*
  • Adult
  • Blood Coagulation / drug effects*
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Humans
  • Hypertension / blood*
  • Isoproterenol / administration & dosage
  • Isoproterenol / pharmacology*
  • Male
  • Middle Aged
  • Propranolol / pharmacology*
  • von Willebrand Factor / antagonists & inhibitors
  • von Willebrand Factor / metabolism

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Fibrin Fibrinogen Degradation Products
  • von Willebrand Factor
  • Propranolol
  • Isoproterenol